What is the recommended inpatient treatment regimen for community‑acquired pneumonia?

Inpatient Treatment for Community-Acquired Pneumonia

For hospitalized patients with community-acquired pneumonia not requiring ICU admission, use either a respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily) OR a β-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus a macrolide (azithromycin or clarithromycin). 1

Non-ICU Inpatient Treatment

The IDSA/ATS guidelines provide two equally effective options with strong evidence:

Option 1: Respiratory Fluoroquinolone Monotherapy

• Levofloxacin 750 mg IV daily
• Moxifloxacin 400 mg IV daily
• This is a strong recommendation with level I evidence 1

Option 2: β-lactam Plus Macrolide Combination

• Preferred β-lactams:
  • Ceftriaxone 1-2 g IV daily
  • Cefotaxime 1-2 g IV every 8 hours
  • Ampicillin-sulbactam 1.5-3 g IV every 6 hours
  • Ertapenem (for selected patients with gram-negative risk factors)
• Plus a macrolide:
  • Azithromycin 500 mg IV daily
  • Clarithromycin 500 mg IV twice daily
  • Doxycycline 100 mg IV twice daily (alternative)
• This is a strong recommendation with level I evidence 1

Both regimens are therapeutically equivalent for non-ICU patients. The fluoroquinolone may offer convenience with once-daily dosing, while combination therapy provides dual coverage through different mechanisms 1.

ICU-Admitted Patients (Severe CAP)

For severe CAP requiring ICU admission, use a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either azithromycin OR a respiratory fluoroquinolone. This is a strong recommendation. 1

Standard Severe CAP Regimen:

• β-lactam: Ceftriaxone, cefotaxime, or ampicillin-sulbactam
• PLUS azithromycin (level II evidence) OR fluoroquinolone (level I evidence)

Critical point: Fluoroquinolone monotherapy is NOT recommended for ICU patients—combination therapy is mandatory 1.

Special Populations Requiring Modified Coverage

Pseudomonas Risk Factors

If the patient has structural lung disease (bronchiectasis), recent hospitalization with IV antibiotics in past 90 days, or severe COPD requiring steroids:

• Antipseudomonal β-lactam: piperacillin-tazobactam 4.5 g IV q6h, cefepime 2 g IV q8h, imipenem 500 mg IV q6h, or meropenem 1 g IV q8h
• PLUS either:
  • Ciprofloxacin 400 mg IV q8h OR levofloxacin 750 mg IV daily
  • OR aminoglycoside (gentamicin 5-7 mg/kg IV daily) plus azithromycin
  • OR aminoglycoside plus antipneumococcal fluoroquinolone 1

MRSA Risk Factors

If the patient has prior MRSA isolation, recent IV antibiotics within 90 days, or is in a unit with >20% MRSA prevalence, ADD:

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL; consider loading dose 25-30 mg/kg for severe illness)
• OR linezolid 600 mg IV q12h 1

Penicillin Allergy

Use a respiratory fluoroquinolone plus aztreonam 1

Critical Management Principles

Timing of First Dose

Administer the first antibiotic dose while still in the emergency department—do not delay until floor admission 1. This is associated with improved mortality.

Switch to Oral Therapy

Transition from IV to oral antibiotics when the patient meets ALL criteria:

• Hemodynamically stable
• Clinically improving
• Able to ingest medications
• Functioning GI tract
• Afebrile for 48-72 hours (or <100°F on two occasions 8 hours apart) 1

Discharge the same day as oral switch if medically and socially appropriate—inpatient observation on oral therapy is unnecessary 1.

Duration of Therapy

Treat for minimum 5 days (level I evidence), with the patient being:

• Afebrile for 48-72 hours
• Having no more than 1 sign of clinical instability before stopping 1

Recent evidence from 2025 supports even shorter durations (3 days) for patients achieving clinical stability by day 3, though the established guideline minimum remains 5 days 2.

Pathogen-Directed Therapy

Once a pathogen is identified through reliable microbiologic methods, narrow therapy to target that specific organism 1. This reduces unnecessary broad-spectrum exposure.

Common Pitfalls to Avoid

1. Do not use macrolide monotherapy for hospitalized patients—resistance rates make this inadequate 1
2. Do not use fluoroquinolone monotherapy in ICU patients—combination therapy is required 1
3. Do not delay antibiotics waiting for floor bed—give first dose in ED 1
4. Do not continue IV antibiotics once stability criteria are met—early switch reduces complications and costs 1
5. Do not empirically cover MRSA or Pseudomonas without specific risk factors—this promotes resistance 1